Acorda Therapeutics, Inc. (ACOR)
ACOR Price and Sentiment
ACOR Latest news
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Corporate Restructuring, Management Changes
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2021 Results - Earnings Call Transcript
Acorda (ACOR) delivered earnings and revenue surprises of -9.57% and 6.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2021 Financial Results
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acorda Therapeutics Continues To Maneuver For A Turnaround
The stock price of Acorda Therapeutics Inc (NASDAQ: ACOR) increased by over 40% pre-market. This is why it happened.
Acorda Therapeutics Inc (NASDAQ: ACOR) has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A. to commercialize Inbrija 33 mg (levodopa inhalation powder, hard capsules) in Spain.